New model for predicting neuroblastoma outcomes incorporates early developmental signals

July 6, 2018, Stowers Institute for Medical Research
Scientists use insight from neural crest biology and developmental signaling pathways to generate a predictive model for neuroblastoma outcomes. Credit: Kulesa Lab

Neuroblastoma, a rare childhood cancer of the sympathetic nervous system, is particularly deadly because it is difficult to detect and thus generally advanced before treatment begins. Scientists know that neuroblastoma develops from embryonic neural crest cells that fail to properly migrate or differentiate, but the details about exactly what causes these cells to go astray have been unclear.

Motivated by a desire to better understand the molecular circuitry underlying and limitations of current methods for predicting and outcome, researchers from the Kulesa Lab at the Stowers Institute for Medical Research and collaborators at the University of Michigan and Oxford University set out to construct a logic-based incorporating information about developmental signaling pathways implicated in the disease. They sought to test whether their model could predict disease outcomes more effectively than the current predictive methods, which are based on gene expression information from human patient samples but do not provide much insight about how these molecules interact to participate in disease progression.

Using a 6-gene input logic model, the team simulated a molecular network of and downstream signals that predicted a favorable or unfavorable disease outcome based on the outcome of four cell states related to tumor development—cell differentiation, proliferation, apoptosis, and angiogenesis. The six genes of the model included three involved in sympathetic nervous system development and implicated in neuroblastoma—trkA, trkB, and ALK—plus their three ligands.

The researchers checked the predictive value of their model by evaluating a known aggressively growing human neuroblastoma cell line for the six input genes and using that information to predict cell states and disease outcome, which were all confirmed.

Next, they determined the relevance of their model to the human disease population by testing it against a gene expression database of human neuroblastoma patients whose outcomes were known. The model proved to be 91% accurate in predicting outcomes in children less than 2 years old. The accuracy of gene lists, the current approach for predicting outcomes, ranges from 75% to 80%.

Their findings were published online in April 2018 in Biophysical Chemistry, and are already garnering interest from clinicians. The article also appears in the July 2018 issue of the journal.

"Currently, doctors develop therapy strategies based on a combination of historical information about what's worked for patients with similar gene markers and a general set of criteria that may or may not result in an individual patient's favorable outcome," says Jennifer C. Kasemeier-Kulesa, Ph.D., a research specialist at the Stowers Institute and lead author of the study. "Our findings highlight the predictive strength of a logic-based model based on developmental genes and offer a better understanding of the molecular network interactions occurring in neuroblastoma."

The study builds upon research published by the Kulesa Lab in Nature Communications that suggested the role trkB and BDNF signaling play in sympathetic neuron development.

"This model allows us to better understand the mechanics of the of receptor tyrosine kinase signaling and how the interplay between these genes and signals may lead to a favorable or unfavorable outcome in neuroblastoma patients," says Kasemeier-Kulesa. "Within a day, our model could quickly simulate the overexpression or underexpression of a particular gene so that we can start to make predictions about how these play together."

"Another reason this study is exciting for the team is because it's work funded in part by Alex's Lemonade Stand Foundation (ALSF)," said Paul Kulesa, Ph.D., Stowers director of imaging and lab head. "The Innovation Grant awarded to the lab by ALSF allowed us additional freedom to explore some research paths less traveled, such as the construction of computational models."

Explore further: A new target for neuroblastoma

Related Stories

A new target for neuroblastoma

February 15, 2018
Neuroblastoma, a cancer that starts in nerve tissue outside of the brain, is the third most common cancer in children and accounts for about 15 percent of pediatric cancer-related deaths.

A new molecular target to improve neuroblastoma treatment

May 22, 2017
The annual mortality rate in childhood cancer of the sympathetic nervous system, or neuroblastoma, is 10 per million between the ages of zero and four. A collaborative work between Basque and Valencian researchers has identified ...

Researchers identify genes fueling neuroblastoma spread

August 31, 2017
For the first time, Mayo Clinic researchers and colleagues present data on how nervous system tumors, called neuroblastomas, spread. Their paper, published in Cancer Cell, clarifies the relationship between two genes that ...

Oestrogen causes neuroblastoma cells to mature into neurons

January 29, 2018
The female sex hormone oestrogen can perform an important role in neuroblastoma, a form of cancer mainly affecting young children. In laboratory experiments, researchers at Karolinska Institutet in Sweden demonstrate that ...

New biomarkers for neuroblastoma, a type of cancer in children

March 13, 2018
Two new biomarkers for a type of cancer in children called neuroblastoma have been identified in a study published in the journal Cancer Cell. The findings are expected to have immediate significance for disease prognosis, ...

Recommended for you

Supplement may ease the pain of sickle cell disease

July 19, 2018
(HealthDay)—An FDA-approved supplement reduces episodes of severe pain in people with sickle cell disease, a new clinical trial shows.

Enzyme identified as possible novel drug target for sickle cell disease, Thalassemia

July 19, 2018
Medical researchers have identified a key signaling protein that regulates hemoglobin production in red blood cells, offering a possible target for a future innovative drug to treat sickle cell disease (SCD). Experiments ...

Mice given metabolite succinate found to lose weight by turning up the heat

July 19, 2018
A team of researchers with members from institutions across the U.S. and Canada has found that giving the metabolite succinate to mice fed a high-fat diet prevented obesity. In their paper published in the journal Nature, ...

Scientists uncover DNA 'shield' with crucial roles in normal cell division

July 18, 2018
Scientists have made a major discovery about how cells repair broken strands of DNA that could have huge implications for the treatment of cancer.

Researchers develop novel bioengineering technique for personalized bone grafts

July 18, 2018
Scientists from the New York Stem Cell Foundation (NYSCF) Research Institute have developed a new bone engineering technique called Segmental Additive Tissue Engineering (SATE). The technique, described in a paper published ...

Researchers report protein kinase as the switch controlling obesity and diabetes

July 18, 2018
One of the research lines targeting the worldwide obesity epidemic is the manipulation of brown adipose tissue, a 'good' type of fat that burns lipids to maintain an appropriate body temperature. Researchers at the Centro ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.